No price history available.
Key financial summary
Financials in KRW| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | KRWm | 2,471,226 | 3,107,313 | 3,316,778 | 3,210,853 | 3,553,264 | 3,348,427 | N/A | N/A |
| Operating profit | KRWm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | KRWm | 102,313 | 237,701 | 71,009 | 172,366 | 28,270 | -196,840 | N/A | N/A |
| EPS reported | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | KRWm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | KRWm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | KRWm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in KRW| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Samyang Holdings Corporation, a diversified conglomerate founded in Seoul, South Korea, in 1924, engages in a wide array of activities through its various subsidiaries. The company's operations span the chemical, food, packaging, pharmaceutical, and IT service sectors. Its chemical division manufactures an extensive range of advanced materials, including value-added chemicals, terephthalic acid, various polycarbonate (PC) resins, bisphenol-A, and specialized engineering plastics. They also produce PC and polybutylene terephthalate compounds, PET bottles, and long fiber reinforced thermoplastics. In the food business, Samyang offers both health and wellness products and starch-based sugars. The company also extends into consumer services, operating the Seven Springs salad and brunch restaurant concept, along with Café Seven Springs bakeries. Its pharmaceutical arm develops and markets anti-cancer treatments such as Genexol and Nanoxel PM, in addition to medical devices like the NicoStop smoking cessation patch and biodegradable surgical sutures, including Trisorb and Monosorb. Samyang's products have a global reach, being exported to over 80 countries. Furthermore, Samyang provides comprehensive IT services, offering consulting for system management and integration, e-business solutions, and enterprise software (ERP, e-HR, MES, and mobile services) to clients in the public, finance, and manufacturing industries.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Samyang Holdings Corporation (000070.KS)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Samyang Holdings Corporation, a diversified conglomerate founded in Seoul, South Korea, in 1924, engages in a wide array of activities through its various subsidiaries. The company's operations span the chemical, food, packaging, pharmaceutical, and IT service sectors. Its chemical division manufactures an extensive range of advanced materials, including value-added chemicals, terephthalic acid, various polycarbonate (PC) resins, bisphenol-A, and specialized engineering plastics. They also produce PC and polybutylene terephthalate compounds, PET bottles, and long fiber reinforced thermoplastics. In the food business, Samyang offers both health and wellness products and starch-based sugars. The company also extends into consumer services, operating the Seven Springs salad and brunch restaurant concept, along with Café Seven Springs bakeries. Its pharmaceutical arm develops and markets anti-cancer treatments such as Genexol and Nanoxel PM, in addition to medical devices like the NicoStop smoking cessation patch and biodegradable surgical sutures, including Trisorb and Monosorb. Samyang's products have a global reach, being exported to over 80 countries. Furthermore, Samyang provides comprehensive IT services, offering consulting for system management and integration, e-business solutions, and enterprise software (ERP, e-HR, MES, and mobile services) to clients in the public, finance, and manufacturing industries.
